Liya Ding, PhD, is an Instructor in the Department of Cancer Biology at Dana-Farber Cancer Institute and the Department of Medicine at Harvard Medical School. Dr. Ding received her B.E. from Tianjin University of Science & Technology, China and Ph.D. from Fudan University, China. After postdoctoral training in the area of epigenetic regulation of gene expression in cancer initiation and progression at Mayo Clinic, she joined Dr. Jean Zhao’s laboratory at Dana-Farber Cancer Institute and began work on targeted therapy and immunotherapy in ovarian cancer. She generated syngeneic ovarian cancer mouse models and recently reported that PARP inhibitors trigger robust antitumor immunity in Brca1-deficient ovarian tumors. Currently her research interest is centered on developing strategies to overcome therapeutic resistance to PARP inhibition through targeting of both tumor and the tumor microenvironment in ovarian cancer.